Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo

References

• Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16–23.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 2002;100:1148–1158.
   PubMed Web of Science ®Google Scholar
• Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–427.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, et al.; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243–3253.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL, Hubbell FA, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207–1216.
   PubMed Web of Science ®Google Scholar
• Opatrny L, Dell’Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169–75; discussion 175.
   PubMed Web of Science ®Google Scholar
• Gompel A, Malet C, Spritzer P, Lalardrie JP, Kuttenn F, Mauvais-Jarvis P. Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63:1174–1180.
   PubMed Web of Science ®Google Scholar
• Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415–7421.
   PubMed Web of Science ®Google Scholar
• Söderqvist G, Isaksson E, von Schoultz B, Carlström K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123–128.
   PubMed Web of Science ®Google Scholar
• Isaksson E, von Schoultz E, Odlind V, Söderqvist G, Csemiczky G, Carlström K, Skoog L, von Schoultz B. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163–169.
   PubMed Web of Science ®Google Scholar
• Conner P, Christow A, Kersemaekers W, Söderqvist G, Skoog L, Carlström K, Tani E, et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment. Climacteric 2004;7:50–58.
   PubMed Web of Science ®Google Scholar
• Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81:617–623.
   PubMed Web of Science ®Google Scholar
• Conner P, Register TC, Skoog L, Tani E, von Schoultz B, Cline JM. Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys. Am J Obstet Gynecol 2005;193:58–63.
   PubMed Web of Science ®Google Scholar
• Lundström E, Söderqvist G, Svane G, Azavedo E, Olovsson M, Skoog L, von Schoultz E, von Schoultz B. Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study. Fertil Steril 2006;85:989–995.
   PubMed Web of Science ®Google Scholar
• Conner P, Söderqvist G, Skoog L, Gräser T, Walter F, Tani E, Carlström K, von Schoultz B. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159–165.
   PubMed Web of Science ®Google Scholar
• Hofling M, Hirschberg AL, Skoog L, Tani E, Hägerström T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007;14:183–190.
   PubMed Web of Science ®Google Scholar
• Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125–134.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–111.
   PubMed Web of Science ®Google Scholar
• Conner P, Skoog L, Söderqvist G. Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology. Climacteric 2001;4:7–12.
   PubMedGoogle Scholar
• Murkes D, Conner P, Leifland K, Tani E, Beliard A, Lundström E, Söderqvist G. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188–1191.
   PubMed Web of Science ®Google Scholar
• Södergård R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801–810.
   PubMedGoogle Scholar
• Dumas I, Diorio C. Estrogen pathway polymorphisms and mammographic density. Anticancer Res 2011;31:4369–4386.
   PubMed Web of Science ®Google Scholar
• Sahlin L, Norstedt G, Eriksson H. Estrogen regulation of the estrogen receptor and insulinlike growth factor-I in the rat uterus: a potential coupling between effects of estrogen and IGF-I. Steroids 1994;59:421–430.
   PubMed Web of Science ®Google Scholar
• Naciff JM, Hess KA, Overmann GJ, Torontali SM, Carr GJ, Tiesman JP, Foertsch LM, et al. Gene expression changes induced in the testis by transplacental exposure to high and low doses of 17{alpha}-ethynyl estradiol, genistein, or bisphenol A. Toxicol Sci 2005;86:396–416.
   PubMed Web of Science ®Google Scholar
• Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, et al. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 2010;119:305–314.
   PubMed Web of Science ®Google Scholar
• Field LA, Love B, Deyarmin B, Hooke JA, Shriver CD, Ellsworth RE. Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer 2012;118:1334–1344.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867–873.
   PubMed Web of Science ®Google Scholar
• Gompel A, Somaï S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000;65:593–598.
   PubMed Web of Science ®Google Scholar
• Cho H, Aronica SM, Katzenellenbogen BS. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors. Endocrinology 1994;134:658–664.
   PubMed Web of Science ®Google Scholar
• Caruso ML, Gabrieli G, Marzullo G, Pirrelli M, Rizzia E, Sorino F. Core Biopsy as Alternative to Fine-Needle Aspiration Biopsy in Diagnosis of Breast Tumors. Oncologist 1998;3:45–49.
   PubMedGoogle Scholar
• Somerville P, Seifert PJ, Destounis SV, Murphy PF, Young W. Anticoagulation and bleeding risk after core needle biopsy. AJR Am J Roentgenol 2008;191:1194–1197.
   PubMed Web of Science ®Google Scholar
• Isaksson E, Sahlin L, Söderqvist G, von Schoultz E, Masironi B, Wickman M, Wilking N, et al. Expression of sex steroid receptors and IGF-1 mRNA in breast tissue–effects of hormonal treatment. J Steroid Biochem Mol Biol 1999;70:257–262.
   PubMed Web of Science ®Google Scholar
• Kazer RR. Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int J Cancer 1995;62:403–406.
   PubMed Web of Science ®Google Scholar
• Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997;152:39–47.
   PubMed Web of Science ®Google Scholar
• Willett WC, Colditz G, Stampfer M. Postmenopausal estrogens–opposed, unopposed, or none of the above. JAMA 2000;283:534–535.
   PubMed Web of Science ®Google Scholar
• Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 2012;131:49–63.
   PubMed Web of Science ®Google Scholar
• Conner P, Lundström E, von Schoultz B. Breast cancer and hormonal therapy. Clin Obstet Gynecol 2008;51:592–606.
   PubMed Web of Science ®Google Scholar
• Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A. Treatment of skin aging with topical estrogens. Int J Dermatol 1996;35:669–674.
   PubMed Web of Science ®Google Scholar